Abstract:Purpose/Objective(s) Plasma ctHPVDNA is detectable prior to treatment in ∼90% of patients with HPV-OPSCC and has shown utility in the dynamic monitoring of treatment response and detecting recurrences (4, 5, 6). Recent data has demonstrated ctHPVDNA to be detectable in patients with sinonasal and nasopharyngeal primary tumors (7). Herein, we present our early experience of ctHPVDNA detection in non-oropharyngeal HPV-associated head and neck cancers using an ultrasensitive multianalyte droplet polymerase chain reaction assay that tests for cell free tumor tissue modified viral (TTMV)-HPV DNA (liquid biopsies). Materials/Methods The medical record of all head and neck cancer patients at our institution seen from April 2022-September 1, 2023 were reviewed. HPV status was determined by immunohistochemical staining of tumor tissue for p16 and in-situ hybridization for high risk subtypes of HPV, per our institutional standard procedures. TTMV-HPV DNA results, patient demographic information, clinical data, and were obtained from chart review. Results We identified 20 patients with non-oropharyngeal HPV-associated head and neck cancers in whom TTMV-HPV DNA was assessed. All cancers were p16 positive and HPV was tested in 8/20 and was positive in 7/8. Of these 20 patients, 15 patients had assessment TTMV-HPV DNA prior to treatment. This included 3 patients with SCC of the nasopharynx, 3 patients with sinonasal SCC, 1 patient with SCC of the posterior pharyngeal wall, 3 patients with SCC of unknown primary, 1 patient with SCC of the oral tongue, 2 patients with SCC of the larynx, 1 patient with cutaneous SCC, and one patient with sinonasal neuroendocrine carcinoma of the ethmoid sinus. Pre-treatment TTMV-HPV DNA was detectable in 13/16 with a median value of 7,808 (range 0-98,950). 11 had TTMV-HPV16 DNA positivity, 1 -HPV18, 0-HPV 33, 1 -HPV 35. TTMV-HPV DNA was undetectable in patients with the following primary sites: T4N0 subglottic SCCA (HPV positive), and pT2N0 SCC of the nasal cavity (HPV positive). Conclusion Circulating TTMV-HPV DNA is detectable in non-oropharyngal HPV-associated head and neck cancers. More research is needed to validate the sensitivity, specificity, and clinical utility of TTMV-HPV DNA in non-oropharyngeal HPV-associated head and neck cancers.

Application of Human Papillomavirus‐DNA Test on Salivary Gland Fine Needle Aspiration Cytology Samples Confirms the Absence of the Virus in Primary Neoplasms and Demonstrates for the First Time Its Presence in Salivary Intraglandular Cysts

Parotid squamous cell carcinoma metastases: Application of human papillomavirus ‐DNA test on liquid‐based cytology to recognize oropharyngeal origin of the neoplasm

DETECTION OF HUMAN PAPILLOMAVIRUS IN SALIVARY GLAND TUMORS

Searching beyond the usual papillomavirus suspects in squamous carcinomas of the vulva, penis and head and neck

A pilot study on salivary HPV DNA detection to monitor active disease from patients with recurrent respiratory papillomatosis

Feasibility Of Quantitative Pcr-Based Saliva Rinse Screening Of Hpv For Head And Neck Cancer

Erratum: Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. (Cancer. (2015) 121 (3455-3464))

Are HPV oncogenic viruses involved in salivary glands tumorigenesis?

Feasibility of Quantitative PCR‐based Saliva Rinse Screening of HPV for Head and Neck Cancer

Human papillomavirus circulating tumor DNA: a diagnostic tool in squamous cell carcinoma of unknown primary—a pilot study

Assessment of hepatitis c core antigen in epithelial salivary gland neoplasms (ex-vivo study)

Human Papilloma Virus (HPV) Detection in Oral Rinse vs. Oral Sponge: A Preliminary Accuracy Report in Oral Cancer Patients

Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study

The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas

The relationship of C-erbB-2、PCNA and infections of HPV in salivary gland tumors

Targeting Viral DNA and Promoter Hypermethylation in Salivary Rinses for Recurrent HPV-Positive Oropharyngeal Cancer.

Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer

Detectable Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA in Non-Oropharyngeal Head and Neck Cancers

A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16INK4a expression in head and neck squamous cell carcinoma patients

Circulating Human Papillomavirus DNA As a Marker for Disease Extent and Recurrence among Patients with Oropharyngeal Cancer

Cytology, High-Risk Human Papillomavirus Testing and Serum CA19-9 in a Large Cohort of Patients with Invasive Cervical Adenocarcinomas: Correlation with a New Pathogenetic Classification.